Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -105% Improvement Relative Risk HCQ for COVID-19  De Luna et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 150 patients in Dominican Republic Study underpowered to detect differences De Luna et al., medRxiv, December 2020 Favors HCQ Favors control

Clinical and Demographic Characteristics of COVID-19 Patients Admitted in a Tertiary Care Hospital in the Dominican Republic

De Luna et al., medRxiv, doi:10.1101/2020.12.11.20247437
Dec 2020  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 150 patients in the Dominican Republic, 132 treated with HCQ, showing higher mortality with treatment in unadjusted results. Confounding by indication is likely.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details; substantial unadjusted confounding by indication likely.
risk of death, 104.5% higher, RR 2.05, p = 0.69, treatment 15 of 132 (11.4%), control 1 of 18 (5.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
De Luna et al., 14 Dec 2020, retrospective, Dominican Republic, preprint, 10 authors.
This PaperHCQAll
Clinical and Demographic Characteristics of COVID-19 Patients Admitted in a Tertiary Care Hospital in the Dominican Republic
David De Luna, Yori Roque, Nicolás Batlle, Katherine Gómez, Miguelina Jáquez, Brinia Cabrera, Lissa De La Cruz, Osvaldo Tavárez, Rossy Belliard, José Javier Sanchez
To present clinical and demographic characteristics of COVID-19 patients admitted to Hospital Metropolitano de Santiago in Dominican Republic, we analyzed electronic medical records of all hospitalized patients clinically admitted as viral pneumonia through March -April, 2020. Of 374 patients, 150 (40.1%) laboratory confirmed, were included in this study. Most of the patients were men (104 / 69.3%) with a median (IQR 44 -66) age of 54. Hypertension (83 / 55.3%) and diabetes mellitus (49 / 32.7%) were the most common comorbidities, whereas fever (120 / 80%), cough (79 / 52.7%) and fatigue (60 / 40%) were the most common presenting symptoms. 28 (18.7%) patients required admission to the intensive care unit, of them, 26 patients (17.3%) required mechanical ventilation. The overall mortality rate was 10.7% Higher levels of inflammatory markers were associated with longer length of stay (LOS). This findings indulge information that could contribute to stratify patients at higher risk of complications.
Baqui, Bica, Marra, Ercole, Van Der Schaar, Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study, Lancet
Becze, Molnair, Fazakas, The Molecular Basis of Procalcitonin Synthesis in Different Infectious and Non-Infectious Acute Conditions, J Hum Virol Retrovirol, doi:10.15406/jhvrv.2016.03.00085
Berenguer, Ryan, Rodríguez-Baño, Jarrín, Carratalá et al., The COVID-19@Spain Study Group. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain, doi:10.1016/j.cmi.2020.07.024
Chen, Lu, Melino, COVID-19 infection: the China and Italy perspectives, Cell Death Dis
Colaneri, Sacchi, Zuccaro, Biscarini, Sachs et al., COVID19 IRCCS San Matteo Pavia Task Force. Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28, Euro Surveill, doi:10.2807/1560-7917.ES.2020.25.16.2000460
Domingo, Rd, Gobierno de la República Dominicana, Salud Pública. Dirección General de Epidemiología
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, doi:10.1101/2020.03.16.20037135
Goyal, Choi, Pinheiro, Schenck, Chen et al., Clinical Characteristics of Covid-19 in New York City, N Engl J Med, doi:10.1056/NEJMc2010419
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., The COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy, JAMA
Guang, Ni, Hu, Liang, Ou et al., The China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, doi:10.1056/nejmoa2002032
Kaur, Gupta, Singh, Karia, Ashraf et al., Epidemiological and Clinical Characteristics of 6635 COVID-19 Patients: a Pooled Analysis, SN Compr Clin Med, doi:10.1007/s42399-020-00393-y
Lai, Wang, Hsueh, Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?, J Microbiol Immunol Infect, doi:10.1016/j.jmii.2020.05.013
Lansbury, Lim, Baskaran, Lim, Co-infections in people with COVID-19: a systematic review and meta-analysis, J Infect, doi:10.1016/j.jinf.2020.05.046
Lechien, Chiesa-Estomba, Place, Van Laethem, Cabaraux et al., COVID-19 Task Force of YO-IFOS. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019, J Intern Med, doi:10.1111/joim.13089
Lee, Sewa, Phua, Potential role of statins in COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.05.115
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA
Roche, Hoffmann-La Roche
Rodríguez-Baño, Pachón, Carratalá, Ryan, Jarrín et al., cohort study (SAM-COVID-19)
Xu, Han, Li, Sun, Wang et al., Effective treatment of severe COVID-19 patients with tocilizumab, PNAS
Ye, Lio, Xia, Sun, Ding et al., Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019, Eur Rev Med Pharmacol Sci, doi:10.26355/eurrev_202003_20706
Zhang, Dong, Can, Yuan, Yang et al., Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy, doi:10.1111/all.14238
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop